Drug Profile
Omeprazole extended release - Assertio Therapeutics
Alternative Names: DM-3458Latest Information Update: 06 Nov 2021
Price :
$50
*
At a glance
- Originator Depomed
- Developer Assertio Therapeutics
- Class 2 pyridinylmethylsulfinylbenzimidazoles; Antiulcers; Gastric antisecretories; Small molecules
- Mechanism of Action Proton pump inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Gastro-oesophageal reflux
Most Recent Events
- 15 Aug 2018 Depomed is now called Assertio Therapeutics
- 15 Aug 2006 Phase-I clinical trials in Gastro-oesophageal reflux in USA (PO)
- 02 May 2005 Preclinical trials in Undefined in USA (unspecified route)